Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cacd466317f39044a5d62488392e3d6b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20262 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16334 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16171 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
filingDate |
2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_793dffd4451c18ed421ea4530d6f773d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd91fe7fcd4385ce482eeb8cbf99f2a6 |
publicationDate |
2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9737597-B2 |
titleOfInvention |
Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins |
abstract |
The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51. Another M protein mutant includes a glycine changed to a glutamic acid at position 22 and a methionine changed to an arginine at positions 48 and 51. Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position 22, a leucine changed to a phenylalanine at position 110 and a methionine changed to an arginine at positions 48 and 51. The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher. |
priorityDate |
2011-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |